New hope for cancer wasting: Appetite-Boosting drug under study
NCT ID NCT07243379
First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study looks at whether nanocrystalline megestrol acetate can improve appetite and weight in people with cancer cachexia—a condition where patients lose weight and muscle. About 495 adults with cancer will take the drug daily for up to 12 weeks. Researchers will check appetite at 4 weeks and weight changes over time. It's a real-world study, meaning it observes how the drug works in everyday medical practice.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Nanocrystalline megestrol acetate (a hormone-like drug to boost appetite)
What this could lead to
If it works, this could provide a reliable way to improve appetite and prevent weight loss in people with cancer-related wasting.
What could go wrong
This is an observational study, not a controlled trial, so results may be less definitive. The drug may not work for everyone and could have side effects like blood clots or fluid retention.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CLINICAL CHARACTERISTICS AND TREATMENT OUTCOMES OF MALIGNANT TUMOR CACHEXIA are added.
By submitting, you agree to our Terms of use
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Henan Cancer Hospital, Affiliated to Zhengzhou University
RECRUITINGZhengzhou, Henan, 45000, China
Contact Phone: •••-•••-•••• Email: •••••@•••••